212 results about "Weight gain" patented technology

The invention belongs to the technical field of microorganisms, discloses a strain of pseudomonas putida and application of the strain of pseudomonas putida as fish probiotics, and particularly discloses a strain of pseudomonas putida. The invention provides a symbiotic pseudomonas putida CD separated from fish, and the strain has relatively strong fat utilization capability, can generate a plurality of beneficial extracellular metabolites, can promote metabolism of fish lipids, carbohydrates and proteins and weight gain, and also can improve the iron content and hemoglobin content in fish tissues. The pseudomonas putida strain CD disclosed by the invention has good biological safety, and has a wide development prospect in the aspect of application as fish probiotics.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the technical field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for improving obesity and metabolic syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 28 parts of radix astragali seu hedysari, 8 to 20 parts of radix codonopsis, 20 to 35 parts of rhizoma dioscoreae, 8 to 24 parts of semen lablab album, 6 to 20 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 20 to 35 parts of raw semen coicis, 3 to 10 parts of rhizoma pinelliae preparata, 6 to 15 parts of pericarpium citri reticulatae, 10 to 20 parts of poria cocos, 6 to 15 parts of rhizoma alismatis, 6 to 15 parts of raw liquorice root, 10 to 20 parts of semen hoveniae, 10 to 20 parts of lotus leaf and 8 to 15 parts of raw fructus crataegi. The composition has the effects of invigorating spleen, replenishing qi, resolving dampness and removing turbidity, can effectively control the weight gain of obese patients and improve the metabolic disorder condition of metabolic syndrome, is safe, effective and stable, has small side effects, and has very good research and development values.

Described herein are compounds of Formula I:and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and / or T2DM.

Described herein are compounds of Formula (I): I and their pharmaceutically acceptable salts, wherein R1, R2, R3, Rp, A1, L1, L2, T1, T2, T3, T4, n1, t1, t2, and t3 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and / or T2DM.

This disclosure provides methods for treating a condition or disease associated with weight gain that include administration of an apelin receptor agonist alone or in combination with a GLP-1 receptor agonist. Methods for increasing total weight loss in the subject relative to weight loss that would be caused by administration of a pre-determined amount of a GLP- 1 receptor agonist alone are also provided. In some embodiments, the method is for preserving, or maintaining muscle mass, muscle function, and / or muscle strength in a subject undergoing weight loss therapy. Also provided are method of treating diabetes or diabetic obesity. Also provided are method of treating heart failure with preserved ejection fraction. Also provided are pharmaceutical compositions, such as fixed dose combinations, that include an apelin receptor agonist and a GLP-1 receptor agonist. In some embodiments, the pharmaceutical composition is formulated for oral administration.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

Use of Mycobacterium vaccae, for example strain ATCC 15483, for the treatment or prevention of weight gain, visceral adipose tissue (VAT), obesity, obesity-related metabolic diseases and stress-related disorders.

The invention discloses a micropterus salmoides intestinal function feed additive based on composite synergy and application thereof, and belongs to the technical field of feed additives. The feed additive for improving the intestinal function of the largemouth bass comprises the following raw materials: clostridium butyricum, tributyrin, aspergillus niger and a plant source carrier. The invention provides a compound feed additive capable of remarkably improving the growth performance of the largemouth bass, improving the digestive enzyme activity of the intestinal tract and optimizing the intestinal barrier, and the compound feed additive can remarkably improve the weight gain rate and the specific growth rate of the largemouth bass, remarkably improve the digestive enzyme activity of the intestinal tract of the largemouth bass and maintain the integrity of the tissue structure of the intestinal tract. Compared with a single additive, the compound additive shows a better synergistic gain effect in the aspect of comprehensive effects, has important value for promoting research, development and practical application of novel feed additives of micropterus salmoides, has good popularization and application prospects, and is expected to bring remarkable economic benefits to the breeding industry.

The application relates to the technical field of beef cattle breeding, and particularly discloses a compound preparation for promoting the feed intake, daily weight gain and improving the meat quality of beef cattle and application thereof, which is prepared from the following components in percentage by volume: 40% of micro-ecological preparation, 30% of hawthorn, 10% of medicated leaven, 10% of malt, 5% of areca nut and 5% of dried tangerine or orange peel; the compound preparation is prepared from microorganisms and multiple natural Chinese herbal medicines in a specific and scientific matching ratio; experiments prove that the compound preparation can increase the feed intake of beef cattle by 11.33%, increase the daily weight gain by 16.16%, and significantly shorten the breeding cycle; meanwhile, the contents of aspartic acid, threonine, glutamic acid, alanine, valine, isoleucine, leucine, tyrosine, phenylalanine, lysine, arginine and proline in the muscle are significantly increased, the nutritional quality and flavor taste of beef are effectively improved, the preparation is natural, residue-free and side-effect-free, the preparation method is simple, the cost is low, and the preparation has extremely high practical value and popularization prospect.

The invention discloses a traditional Chinese medicine composition which comprises the following components in parts by weight: 60-80 parts of pithecellobium clypearia, 4-11 parts of jasminum elongatum, 4-11 parts of Chinese knotweed herb, 4-11 parts of ovateleaf holly bark, 2-8 parts of gardenia, 1-6 parts of radix sophorae flavescentis, 1-3 parts of poria cocos and 1-6 parts of citrus chachiensis hortorum. The traditional Chinese medicine composition takes south medicine as a formula component, can replace antibiotics widely used in the pig breeding industry, realizes prevention and / or treatment of pig diarrhea, can improve the pig performance of pigs, including pig daily gain and feed conversion rate, also can improve the natural resistance of the pigs, reduces the occurrence of diseases, and improves the immunity of the pigs. The dependence of pigs on antibiotics is further reduced.

The utility model provides a steel wire rod self-teasing cat stick with a water injection base, and relates to the technical field of pet supplies. Comprising a plastic base, a cavity is formed in the base and used for water injection and weight increment, a water injection opening is formed in the top and sealed through a plug, water source leakage is prevented, a water source is injected into the cavity in the base through the water injection opening, the gravity center of the base is increased, and therefore the anti-toppling performance of the base is improved. The base injects water or sand into the cavity through the water injection opening, the gravity center is greatly lowered, and toppling caused by collision of pets is prevented, so that the pet teasing rod is suitable for different environments, the modular pet teasing rod can adjust the height, is convenient to install and is matched with various use scenes such as a table top and the ground, the pet continuously swings under the action of external force during playing through the design of the elastic rod, and the pet teasing effect is improved. The cats are stimulated to catch by themselves, and manual intervention is reduced. When water or sand in the cavity is discharged, the overall weight is small, and storage and transportation are convenient.

The disclosure provides methods and uses of CCL5 variants for modulating GPR75 signaling in a cell or subject, treating a GPR75-related disease or disorder in a subject, treating obesity, hypertension, metabolic syndrome, metabolic dysfunction-associated steatohepatitis, and / or diabetes in a subject, and inducing weight loss and / or preventing weight gain in a subject, wherein the CCL5 variant comprises a variant N-terminal portion and a C-terminal portion with at least 70% identity to the corresponding portion of wild type CCL5.

The utility model relates to the technical field of livestock breeding equipment, and discloses an anti-blocking feeding bottle for calves, which comprises a feeding bottle main body. According to the anti-blocking feeding bottle for the calf, in order to enable the practicability of the feeding bottle body to be higher, the feeding assembly is arranged and matched with high-elasticity silica gel, food-grade antibacterial silica gel and an aramid fiber net to enhance the structural strength, deformation caused by long-term use is prevented, and the feeding bottle is more sanitary; the flow speed sensor, the temperature sensor, the attitude sensor and the miniature RFID reader are matched to monitor the flow speed, temperature and attitude of the feeding bottle respectively, subsequent operation is facilitated, the annular frame, the inner annular ring, the middle annular ring, the outer annular ring, the inner annular plate and the outer annular plate are matched to adjust the conveying amount of liquid in the feeding bottle in real time, blocking is avoided, milk choking is prevented, the weight increasing efficiency is improved, and the labor intensity of workers is reduced. The disease early warning accuracy is improved, the manual inspection workload is reduced, accumulated feeding big data can be used for optimizing pasture management, and then the practicability of the feeding bottle body is higher.

The present disclosure provides peptides for reducing weight and / or preventing weight gain comprising a GLP-1R agonist. As described herein, the GLP-1R agonist can be administered orally to a subject.

Disclosed herein are a means to prevent and / or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health.

Provided herein are stable aqueous pharmaceutical compositions and formulation comprising non-naturally occurring melanocortin antagonist analogs. The non-naturally occurring melanocortin antagonist analogs may be antagonists of the melanocortin 3 receptor and / or melanocortin 4 receptor.

Nutraceutical food supplement for treatment of young women in post-puberty age suffering from polycystic ovary syndrome with symptoms like irregular menstruation cycles, insulin resistant diabetes, infertility, hair loss, acne and weight gain is provided. Formulations having myo-inositol and its D-chiro isomer along with plant proteins, a carbohydrate (inulin) and other plant fibres; along with well-defined proportions of vitamins (A, B1 to 6; B12 and C); several minerals like Ca, Cr, Fe, K, Mg, Mn, Na and Zn and essential amino acids like L-Glutamine, L-Lysine, and L-Taurine are provided.

Provided is a Bifidobacterium bifidum strain, Bifidobacterium bifidum ibiome001, which can significantly reduce body weight gain and white adipose tissue weight gain of high fat diet-induced obese and diabetic mice, and enhances expression of lipolytic genes ATGL and HSL. Moreover, Bifidobacterium bifidum ibiome001 can significantly lower fasting blood glucose levels, area under curves (AUCs) of the oral glucose tolerance (OGTT) curve, plasma glycated hemoglobin levels and insulin levels of diabetic mice. It is suggested that Bifidobacterium bifidum ibiome001 is a promising potential probiotic strain for the treatment of metabolic syndrome such as obesity, diabetes and the like, which is more effective than other Bifidobacterium strains / compositions.

The application discloses a norchizhiol triterpenoid compound, a preparation method and application thereof. The norchizhiol triterpenoid compound norchizhiol A can be quickly prepared from Ganoderma lucidum. The test proves that the norchizhiol A can inhibit the accumulation of triglyceride in the differentiation process of 3T3L1 preadipocytes. The norchizhiol A can also effectively reduce the weight increase and liver coefficient of high-fat-diet-induced obese mice, regulate the blood lipid level of the obese mice, and significantly intervene and improve the lipoprotein distribution of the body. The compound can be used for preparing anti-obesity and lipid-lowering medicines.

This invention discloses the application of α-hydroxyisocaproic acid in weight loss and lipid reduction, belonging to the fields of biopharmaceutical manufacturing, biomedical applications, and functional food development. This invention confirms the application of α-hydroxyisocaproic acid in weight loss; this compound can inhibit weight gain in high-fat diet-induced obese mouse models, reduce body fat, and decrease the area of ​​adipocytes in high-fat diet-induced obese mouse models. Compared to GLP-1 receptor weight-loss drugs that reduce weight by suppressing appetite, the compound α-hydroxyisocaproic acid intervenes in and prevents obesity by accelerating fat metabolism, thereby achieving weight reduction. This invention provides a safe and effective new strategy for weight loss and lipid reduction.

Provided herein, inter alia, are compositions of organic acid-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

The invention discloses a traditional Chinese medicine monomer composition derived from chrysanthemum plants and used for treating diabetic retinopathy as well as a preparation method and application of the traditional Chinese medicine monomer composition. The traditional Chinese medicine monomer composition prepared from the chrysanthemum plant as the raw material is high in safety, small in side effect and definite in component and is prepared according to a specific ratio, and pharmacodynamic experiments prove that compared with an ethanol extract, the traditional Chinese medicine monomer composition is more remarkable in curative effect on diabetic retinopathy, and the curative effect of the traditional Chinese medicine monomer composition on diabetic retinopathy is better than that of a traditional Chinese medicine composition on diabetic retinopathy. The composition can improve the pathological state of diabetic retinopathy from multiple targets and multiple ways, specifically can inhibit body mass increase caused by high glucose, reduce blood glucose level, improve retinal tissue structure damage, recover retinal tissue thickness, inhibit retinal cell apoptosis and inflammatory response, reduce the expression level of HIF-1alpha and VEGF protein in retinal tissue, and can be used for treating diabetic retinopathy. Scientific basis and technical support are provided for research and development of novel drugs for treating the diabetic retinopathy, and important clinical significance and market application prospects are achieved.

The disclosure pertains to a medicinal preparation having a mixture of diarylheptanoid complexes and essential oil of turmeric embedded in diarylheptanoid metal complex. It also discloses a method of preparation in which the complex is formed by the reaction of diarylheptanoids with a cation in the presence of oil. Diarylheptanoid metal complexes with embedded oil show improvement in the general health of avians and mammals. Improvements in avians and mammals health include reduced mortality, improved weight gain, improved meat quality, improved bone density, improved eggshell thickness, improved immunomodulatory activity, improved liver conditions, and reduced occurrence of drug-induced dyslipidemia. It is also found that said medicinal preparation is very effective in the prevention of the incidence of udder inflammation and in the treatment of hypocalcemia, Alzheimer's disease, and stress related issues. It has antioxidant activity as well as improved analgesic properties.

The invention provides an efficient muscle and weight gaining nanoemulsion and a preparation method thereof. The nanoemulsion is an O / W type nanoemulsion, a water phase coats creatine through maltodextrin to form a slow-release carrier, curcumin and inulin are coated in a double-layer mode in combination with phospholipid, intestinal cell absorption is enhanced through micelle membrane fusion, and the synergistic effect of curcumin anti-inflammation and inulin regulation flora is achieved; the oil phase adopts a chitosan-sodium alginate polymer to embed a BCAA / MCT compound, branched chain amino acid is released in an intestinal tract in a targeted manner to activate an mTOR pathway, MCT is slowly released to continuously supply energy, gastrointestinal discomfort caused by sudden rising of osmotic pressure is avoided, and the muscle and weight gaining efficiency is remarkably improved through a multi-component synergistic controlled release technology.

The invention discloses a fattening feed additive composition for old cattle and a fattening method, and belongs to the technical field of feed. The additive composition comprises the following components in parts by weight: 13-20 parts of a rumen function regulator, 4-10 parts of an intestinal repair agent, 10-20 parts of a rumen bypass compound enzyme preparation, 5-10 parts of a muscle-increasing growth-promoting composition, 5.5-7.3 parts of a functional trace element composition and 32.7-62.5 parts of a carrier. Wherein the rumen function regulator is compounded by a coated saccharomyces cerevisiae culture and bacillus subtilis; the rumen bypass compound enzyme preparation comprises acid protease, neutral protease and cellulase; the muscle-building and growth-promoting combination is coated guanidinoacetic acid. Through regulation and control of a rumen-intestinal tract-tissue three-level linkage network, the rumen fermentation function of the old cattle is remarkably improved, the feed conversion rate is increased, and meanwhile muscle hyperplasia and meat tenderization are achieved. By means of the fattening method, the average daily gain of the old cattle is increased by 22.8% or above, the muscle shear force is reduced by 29.6% or above, the feed conversion ratio is reduced by 17.1% or above, and green and efficient fattening is achieved.

The invention belongs to the field of biological detection, and particularly relates to a blood protein characteristic polypeptide, a detection kit and application of the blood protein characteristic polypeptide to identification of adulteration and weight gain of hirudo nipponia. And the sequence of the blood protein marker polypeptide is LLGNVIVVVLAR. On the basis of constructing a species marker polypeptide identification method, a heterologous blood protein traceability analysis strategy is introduced, beta globin in blood of common livestock such as pigs, cattle, sheep, horses, donkeys and the like is subjected to multiple sequence alignment, and highly conservative species-independent marker polypeptide is screened out as a chemical marker; and a multi-reaction monitoring (MRM) non-standard quantitative peak area ratio judgment and detection method based on a liquid chromatography-triple quadrupole mass spectrometry technology is established, so that a scientific judgment basis is provided for the problem of blood doping and weight increment.

The application discloses Bifidobacterium Pseudocatenulatum and application thereof, and the Bifidobacterium Pseudocatenulatum YSBP01CCTCC NO: M 20232067. Experiments prove that the Bifidobacterium Pseudocatenulatum can enhance the antioxidant capacity of Caenorhabditis elegans, prolong the life of the nematode, improve the activity and the reproductive capacity of the nematode, reduce fat accumulation, improve the mitochondrial membrane potential, and delay the aging of the body. The Bifidobacterium Pseudocatenulatum can also significantly inhibit the weight increase of a high-fat-diet mouse, reduce the TG level in serum of the mouse, significantly reduce the fasting blood glucose concentration, and effectively prevent and relieve obesity and type 2 diabetes.

The application of unilateral or bilateral permanent prostheses to the labium majus in the external genitalia of women for reconstructive and aesthetic purposes may make it appear fuller. The labium majus may lose its fullness and symmetry due to menopause, rapid weight gain and loss, traumas, cancers, and infectious diseases. Aesthetic interventions (e.g., hyaluronic acid filler injection and fat grafting) aiming to provide the labium majus with fullness have become very popular in recent years. The hyaluronic acid filler is used for reconstructive purposes to achieve fullness in labium majus. However, the maximum amount that can be injected is 3 mL, which is often insufficient for the desired outcome and its effect lasts for a maximum of 1 year. Autologous fat grafting is administered by taking 18–120 mL of fat from patients themselves; however, its effect usually lasts 1 to 4 years. The application of a prosthesis will provide labium majus with fullness and this effect will be long-lasting. The outer edge of the prosthesis is convex and the inner edge is concave. In male genitalia, prostheses have been used since 1950 to provide the testicles with fullness. Scientific studies have shown that these prostheses positively affect self-confidence and body perception indices in men.

The invention discloses kynurenic acid with an effect of relieving vomitoxin toxicity, and belongs to the technical field of agricultural animals. The application proves that the kynurenic acid can effectively relieve the toxic effect induced by vomitoxin, and the kynurenic acid mainly has the effects of effectively promoting the weight gain of animals, improving the intestinal motility function, inhibiting the release of inflammatory factors, regulating intestinal flora and the like. The invention determines the effect of kynurenic acid in relieving vomitoxin toxicity, and the kynurenic acid has a wide application prospect in preparation of products for preventing and treating vomitoxin toxicity.